(secondQuint)Study of Antibody for Methamphetamine Outpatient Therapy.

 IXT-m200 is a monoclonal antibody that binds to methamphetamine in the blood.

 The main purpose of this study is to look at the effects of IXT-m200 on the pharmacokinetics of methamphetamine and on methamphetamine liking effects.

 Additionally, the study will determine IXT-m200 pharmacokinetics, safety and tolerability in subjects with methamphetamine use disorder.

 Qualified subjects will receive a single dose of IXT-m200 followed by up to 4 methamphetamine challenge doses.

.

 Study of Antibody for Methamphetamine Outpatient Therapy@highlight

This study evaluates the ability of IXT-m200 to change methamphetamine concentrations in blood and alter the way methamphetamine feels.

 Participants will receive either placebo, a low or high dose of IXT-m200, in addition to methamphetamine challenge doses.

